The European Federation for Exploratory Medicines Development (EUFEMED) yesterday posted a statement about the widely reported death and serious illnesses occurring in an exploratory clinical trial in Europe (link PRNewswire).
EUFEMED is headquartered in Brussels and constitutes the federated member associations of professionals working in Early Phase clinical trials from Belgium (BAPU), France (Club Phase 1), Germany (AGAH) and the United Kingdom (AHPPI).